Sun Pharma Q1FY27 Results were announced on July 31, 2026, when Sun Pharmaceutical Industries Limited reported consolidated financial results for the first quarter of financial year 2027, the period ended June 30, 2026. The company posted quarterly sales of Rs. 151,836 million, a year-on-year increase of 10.1%, driven by strong momentum in India Formulations and continued expansion of the Global Innovative Medicines portfolio. Net profit for the quarter rose to Rs. 28,948 million, while adjusted net profit came in at Rs. 30,894 million, up 3.1% over the same quarter last year.
The Sun Pharma Q1FY27 Results were disclosed through a press release filed with the Mumbai-headquartered company’s investor relations office and shared with the National Stock Exchange of India and BSE, where the stock trades under the symbols SUNPHARMA and 524715, respectively. Kirti Ganorkar, Managing Director of Sun Pharmaceutical Industries Limited, attributed the quarter’s performance to robust momentum in India as well as the Innovative Medicines franchise, which delivered growth across the U.S. and international regions. He also pointed to recent semaglutide approvals in India, Brazil and South Africa as evidence of the company’s capabilities in developing complex peptide products for patients globally.
On profitability, the Sun Pharma Q1FY27 Results showed EBITDA of Rs. 44,177 million, up 2.7% year-on-year, translating into an EBITDA margin of 28.9%. Research and development investment totaled Rs. 8,264 million, equivalent to 5.4% of sales, underscoring the company’s continued commitment to building its innovative and generic pipeline. Global Innovative Medicines sales reached US$ 351 million for the quarter, up 12.8% and now accounting for 21.9% of total consolidated sales.
Sun Pharma Q1FY27 Results Show Broad-Based Segment Growth Across India, US and Emerging Markets
India Formulations, the company’s largest reporting segment, generated sales of Rs. 54,749 million in the quarter, up 16% year-on-year and representing 36.1% of total consolidated sales. Sun Pharma continues to be India’s No. 1 pharmaceutical company, with market share rising to 8.5% from 8.2% according to the Pharmarack MAT June-2026 report. The company also holds the No. 1 ranking by prescriptions across 12 different doctor categories, per the SMSRC report covering March-June 2026, and launched five new products in the Indian market during the quarter.
US Formulations told a different story. Sales in the United States were US$ 427 million, a decline of 9.7% compared with the prior-year quarter, as continued growth in Innovative Medicines only partially offset softness in the generics business. The US market accounted for approximately 26.6% of total consolidated sales for the period. Meanwhile, Emerging Markets formulations sales rose 4.2% to US$ 311 million, contributing 19.4% of consolidated sales, and Rest of World formulations sales came in at US$ 218 million, representing 13.6% of the total.
Sun Pharma’s Active Pharmaceutical Ingredients business, which supports both its own formulation operations and external API customers across geographies, recorded external sales of Rs. 5,972 million, up 10.5% year-on-year. Together, these segment results in the Sun Pharma Q1FY27 Results paint a picture of a company whose India and specialty franchises are compensating for near-term pressure in the US generics business, a pattern that has repeated across several recent quarters for Sun Pharma.
Innovative Medicines and R&D Pipeline Updates Accompany Sun Pharma Q1FY27 Results
Alongside the headline financials, the Sun Pharma Q1FY27 Results included a detailed update on the company’s innovative research and development pipeline, which spans five novel entities currently in clinical stage. The company’s psoriatic arthritis candidate Ilumya has a supplement filed with the US FDA, with a PDUFA date set for October 2026. Fibromun, being developed for soft tissue sarcoma, has completed Phase 2 trials and is progressing toward the start of Phase 3, while its glioblastoma indication remains in Phase 2 ahead of regulatory filing.
GL0034, a candidate for type 2 diabetes, is in Phase 2 with topline data expected during the second half of calendar year 2027. NidlegyTM, for which Sun holds EU and ANZ rights, is under filing with the European Medicines Agency for locally advanced melanoma, while its basal cell carcinoma and cutaneous squamous cell carcinoma indications remain in Phase 2 ahead of regulatory filing. MM-II, a Phase 2-completed candidate targeting pain in osteoarthritis, is being positioned for out-licensing to a commercialization partner.
Sun Pharma Q1FY27 Results: US Generic Portfolio and ANDA Filings
On the US generics side, Sun Pharma reported a comprehensive product offering consisting of approved ANDAs for 558 products, while filings for 119 ANDAs await US FDA approval, including 28 tentative approvals. During the quarter, the company filed three new ANDAs and received approval for six. Sun’s portfolio additionally includes 57 approved NDAs, with 13 NDAs still awaiting US FDA approval, reflecting a pipeline that spans both branded and generic regulatory pathways.
Sun Pharma Q1FY27 Results Reflect Progress on Organon Acquisition and Regulatory Filings
A notable disclosure within the Sun Pharma Q1FY27 Results was confirmation that Organon shareholders have approved the company’s proposed acquisition by Sun Pharma, which remains on track to close in early 2027. Management did not disclose incremental financial terms beyond what has previously been communicated, but the shareholder approval marks a key procedural milestone in a deal that is expected to expand Sun Pharma’s women’s health and biosimilars footprint once completed.
As with all disclosures accompanying the Sun Pharma Q1FY27 Results, the company reiterated that statements in its results announcement describing objectives, projections, or expectations may constitute forward-looking statements under applicable securities laws, and that actual outcomes could differ materially from those expressed. Sun Pharma said it does not undertake any obligation to update such statements except as required by law, a standard disclosure practice for listed pharmaceutical companies reporting quarterly earnings in India.
Sun Pharma Q1FY27 – Consolidated Financial Performance
| Metric | Q1FY27 (Jun 2026) | Q4FY26 (Mar 2026) | Q1FY26 (Jun 2025) | YoY Growth |
|---|---|---|---|---|
| Total Sales (Rs. million) | 151,835.5 | 145,597.5 | 137,860.7 | 10.1% |
| EBITDA (Rs. million) | 44,177 | — | — | 2.7% |
| EBITDA Margin | 28.9% | — | — | — |
| Net Profit (Rs. million) | 28,948 | — | — | — |
| Adjusted Net Profit (Rs. million) | 30,894 | — | — | 3.1% |
| R&D Expenditure (Rs. million) | 8,263.5 | 9,757.3 | 9,028.6 | -8.5% |
| R&D as % of Sales | 5.4% | — | — | — |
Segment-Wise Sales Breakdown (Rs. million / US$ million)
| Segment | Q1FY27 | Q4FY26 | Q1FY26 | YoY Growth | % of Total Sales |
|---|---|---|---|---|---|
| India Formulations | Rs. 54,748.9 mn | Rs. 48,358.9 mn | Rs. 47,211.0 mn | 16.0% | 36.1% |
| US Formulations | US$ 427 mn | — | — | -9.7% | 26.6% |
| Emerging Markets (EM) | US$ 311 mn | — | — | 4.2% | 19.4% |
| Rest of World (ROW) | US$ 218 mn | — | — | — | 13.6% |
| API (external sales) | Rs. 5,972.3 mn | Rs. 6,738.6 mn | Rs. 5,403.7 mn | 10.5% | — |
| Global Innovative Medicines | US$ 351 mn | — | — | 12.8% | 21.9% |
| Total Formulations | Rs. 145,310.1 mn | Rs. 138,466.2 mn | Rs. 131,930.4 mn | — | — |
Innovative Medicines Pipeline & Regulatory Timeline
| Candidate | Indication | Current Phase | Next Milestone |
|---|---|---|---|
| Ilumya | Psoriatic arthritis | Supplement filed with US FDA | PDUFA Date: Oct-2026 |
| Fibromun | Soft tissue sarcoma | Phase 2 completed | Start of Phase 3 |
| Fibromun | Glioblastoma | Phase 2 | Regulatory filing |
| GL0034 | Type 2 diabetes | Phase 2 | Topline data in 2HCY27 |
| NidlegyTM | Locally advanced melanoma | Filing with EMA | Approval and launch |
| NidlegyTM | Locally advanced BCC | Phase 2 | Regulatory filing |
| NidlegyTM | Locally advanced cSCC | Phase 2 | Regulatory filing |
| MM-II | Pain in osteoarthritis | Phase 2 completed | Partnership for commercialization |
